LLY

1,126.9

+3.46%↑

JNJ

228.18

+1.98%↑

ABBV

223.21

+2.13%↑

UNH

395.46

+3.74%↑

MRK

119.52

+3.94%↑

LLY

1,126.9

+3.46%↑

JNJ

228.18

+1.98%↑

ABBV

223.21

+2.13%↑

UNH

395.46

+3.74%↑

MRK

119.52

+3.94%↑

LLY

1,126.9

+3.46%↑

JNJ

228.18

+1.98%↑

ABBV

223.21

+2.13%↑

UNH

395.46

+3.74%↑

MRK

119.52

+3.94%↑

LLY

1,126.9

+3.46%↑

JNJ

228.18

+1.98%↑

ABBV

223.21

+2.13%↑

UNH

395.46

+3.74%↑

MRK

119.52

+3.94%↑

LLY

1,126.9

+3.46%↑

JNJ

228.18

+1.98%↑

ABBV

223.21

+2.13%↑

UNH

395.46

+3.74%↑

MRK

119.52

+3.94%↑

Home・Aandelen Lijst・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Open

SectorGezondheidszorg

4.95 2.48

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.83

Max

5.2

Belangrijke statistieken
By Trading Economics
Inkomsten	36M -3.7M
Verkoop	16M 66M
EPS	0.01
Winstmarge	-5.67
Werknemers	416
EBITDA	57M 15M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+17.39% upside

Dividenden
By Dow Jones
Volgende Winsten	10 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	354M 1.8B
Vorige openingsprijs	2.47
Vorige sluitingsprijs	4.95

Nieuwssentiment

By Acuity

50%

154 / 344 Rangschikking in Healthcare

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 jun 2026, 23:22 UTC

Winsten

Belangrijke Marktbewegers

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 jun 2026, 23:09 UTC

Populaire aandelen

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 jun 2026, 20:51 UTC

Winsten

Costco Reports 15% Sales Growth in May

3 jun 2026, 20:43 UTC

Winsten

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 jun 2026, 23:48 UTC

Marktinformatie

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 jun 2026, 23:48 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

3 jun 2026, 23:35 UTC

Marktinformatie

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 jun 2026, 23:15 UTC

Marktinformatie

Winsten

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 jun 2026, 22:08 UTC

Populaire aandelen

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 jun 2026, 21:54 UTC

Marktinformatie

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 jun 2026, 21:18 UTC

Winsten

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 jun 2026, 21:15 UTC

Winsten

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 jun 2026, 21:13 UTC

Winsten

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 jun 2026, 21:13 UTC

Winsten

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 jun 2026, 21:12 UTC

Winsten

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 jun 2026, 21:09 UTC

Winsten

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 jun 2026, 21:03 UTC

Winsten

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 jun 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

3 jun 2026, 20:43 UTC

Winsten

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 jun 2026, 20:39 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 jun 2026, 20:37 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 jun 2026, 20:35 UTC

Winsten

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 jun 2026, 20:21 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 jun 2026, 20:17 UTC

Winsten

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 jun 2026, 20:17 UTC

Winsten

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 jun 2026, 20:15 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 jun 2026, 20:15 UTC

Winsten

Broadcom 2Q Adj EPS $2.44 >AVGO

3 jun 2026, 20:15 UTC

Winsten

Broadcom 2Q EPS $1.91 >AVGO

3 jun 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

3 jun 2026, 20:15 UTC

Winsten

Broadcom 2Q Rev $22.19B >AVGO

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

17.39% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.67 USD 17.39%

Hoogste 6 USD

Laagste 5 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Maravai LifeSciences Holdings Inc (Class A) - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

154 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.